One of the major problems encountered in FC patients is the onset of serious pulmonary infections characterized by the presence of antibiotic-resistant microorganisms and the search for new antibiotic formulations is a primary objective. The use of nanoparticles (NPs) functionalized with antimicrobial and antibiofilm peptides (AMPs) can increase the effectiveness of conventional therapies. The aim of this project is to produce a new therapeutic formulation based on inhalable and biodegradable NPs of calcium phosphate (CaPs), functionalized with AMPs, able to counteract the formation of biofilm and the viability of microorganisms. Some AMPs have been already characterized and are available in the “collection” of the project consortium. AMP-NPs will be tested on resistant antibiotic strains also isolated from FC patients and assayed on appropriate cell- lines to verify their eventual cytotoxicity. Subsequently, AMP-NP will be employed in vivo tests on appropriate animal models. In case the produced AMP-NPs will show efficacy in vivo experiments, they could be patented and used in pre-clinical experiments for their development as new antibiotics.